Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maria Mercè, Placeres Alsina"'
Publikováno v:
Enfermedades Infecciosas y Microbiología Clínica. 26:23-28
Raltegravir is the first integrase inhibitor approved for the treatment of HIV-1 infection in pretreated adults with evidence of viral replication despite receiving antiretroviral therapy. Raltegravir is administered orally at a dose of 400 mg every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::43a0d5295e927a5fedb7176f0f0122c4
https://doi.org/10.1016/s0213-005x(08)76569-8
https://doi.org/10.1016/s0213-005x(08)76569-8
Publikováno v:
Enfermedades infecciosas y microbiologia clinica. 26
Raltegravir is the first integrase inhibitor approved for the treatment of HIV-1 infection in pretreated adults with evidence of viral replication despite receiving antiretroviral therapy. Raltegravir is administered orally at a dose of 400 mg every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b989355fbd3c0183d3c5d671680c757b
https://pubmed.ncbi.nlm.nih.gov/19572422
https://pubmed.ncbi.nlm.nih.gov/19572422